Risk of death or reinfarc- tion associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113:2906 13. 196. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302 8. 197. Silverman HS, Pfeifer MP. Relation between use of anti-inflammatory agents and left ventricular free wall rupture during acute myocardial in- farction. Am J Cardiol. 1987;59:363 4. 198. Bulkley BH, Roberts WC. Steroid therapy during acute myocardial in- farction. A cause of delayed healing and of ventricular aneurysm. Am J Med. 1974;56:244 50. KEY WORDS: AHA Scientific Statements acute myocardial infarction non ST-elevation myocardial infarction performance measures quality indicators quality measures ST-elevation myocardial infarction 16 Appendix A. STEMI and NSTEMI Performance Measures Performance Measures for Use in Patients With Inpatient STEMI and NSTEMI Inpatient Measures Short Title: PM-1: Aspirin at Arrival PM-1: AMI: Aspirin Received at Arrival Measure Description: Percentage of patients, age 18 y, hospitalized with AMI who received aspirin within 24 h before or after hospital arrival. 